Skip to main content

Ablavar

Generic name: gadofosveset trisodium
Treatment for: Diagnosis and Investigation

EPIX Provides Update Regarding Status of Vasovist Appeal

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 2, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today provided an update regarding the status of its formal appeal to Steven Galson, M.D., director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA), asking the CDER director to approve the company's novel blood-pool imaging agent Vasovist (gadofosveset trisodium injection). The appeal was submitted on February 28, 2007, and the company is currently in discussions with the Agency regarding the appeals process. Based on these discussions, it is now clear that the Agency's decision-making process will extend beyond the originally anticipated 30-day period.

Andrew Uprichard, president of EPIX commented, "We are pleased to have the opportunity to discuss the process and next steps in our appeal with the Agency. Once we have a response from the Agency, which we now expect late in the second quarter, we will update the market accordingly."

About Vasovist

Vasovist is an injectable intravascular contrast agent designed to provide visual imaging of the vascular system through MRA. The initial target indication for Vasovist is for use in magnetic resonance angiography imaging of non-coronary vascular disease. Vasovist has been approved for marketing in 32 countries including all 27 member states of the European Union, Norway, Iceland, Switzerland, Australia and Canada. Vasovist is marketed by Bayer Schering Pharma AG, Germany.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in a Phase 2b clinical trial in major depressive disorder, and PRX-07034, which is in Phase 1 clinical development for the treatment of obesity and cognitive impairment. The company also has a blood-pool imaging agent (Vasovist) approved in 32 countries and marketed in Europe. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics, and Bayer Schering Pharma AG, Germany.

This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing of the FDA's formal response to our appeal regarding Vasovist. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other things: our failure to comply with regulations relating to our products and product candidates, including FDA requirements; failure to obtain the financial resources to complete development of product candidates; the risk that the FDA may interpret the results of our studies differently than we have; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully secure regulatory approval of and market our drug candidates; and risks of new, changing and competitive technologies and regulations in the U.S. and internationally. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission, including our most recent Quarterly Report on Form 10-Q.

Posted: April 2007

Related articles

Ablavar (gadofosveset trisodium) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.